占诺美林与曲司氯铵对急性精神分裂症认知损害的影响:两项3期试验汇总数据的重复验证
该研究汇总两项为期5周的住院急性精神分裂症患者3期试验数据,预设分析比较占诺美林/曲司氯铵与安慰剂对认知复合评分的变化。全样本(N=357)未见显著效应,但在基线认知损害亚组中,占诺美林/曲司氯铵(N=71)较安慰剂(N=66)有显著认知获益(最小二乘均值差=0.31,SE=0.10;d=0.54),且效应量随基线损害阈值更严格而增大(≤-1.5 SD;d=0.80)。
要点
- 全样本(N=357)中占诺美林/曲司氯铵对认知复合评分无显著效应。
- 基线认知损害亚组中,占诺美林/曲司氯铵(N=71)较安慰剂(N=66)认知改善显著(d=0.54)。
- 基线损害阈值≤-1.5 SD时效应量增大(d=0.80),认知改善与症状变化相关性极小。
核心结论
- 在预设的基线认知损害亚组中,占诺美林/曲司氯铵较安慰剂显著改善急性精神分裂症患者的认知,直接重复了早期发现。
- 该认知获益不能归因于症状变化,尽管有充分证据显示其对精神病性症状有效。
- 作者认为需要在稳定期认知损害患者中开展良好对照的试验来评估占诺美林/曲司氯铵的认知增强潜力。
研究设计与样本
- 汇总两项为期5周的住院急性精神分裂症患者3期试验数据,比较占诺美林/曲司氯铵单药与安慰剂。
- 统计分析计划预设在全样本和基线认知损害亚组(≤1 SD低于常模)中比较认知复合评分变化。
主要发现
- 全样本(N=357)中占诺美林/曲司氯铵对认知复合评分无显著效应。
- 基线认知损害亚组中,占诺美林/曲司氯铵(N=71)较安慰剂(N=66)认知获益显著(最小二乘均值差=0.31,SE=0.10;d=0.54)。
- 基线损害阈值更严格(≤-1.5 SD)时效应量增大(d=0.80)。
- 两个治疗组中认知改善与总症状、阳性症状和阴性症状的同期变化相关性极小。
关键数值与推荐
- 基线认知损害亚组定义为认知复合评分≤1 SD低于常模。
- 认知获益效应量:基线损害亚组d=0.54;基线损害阈值≤-1.5 SD时d=0.80。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 作者认为需要在稳定期认知损害患者中开展良好对照的试验来评估占诺美林/曲司氯铵的认知增强潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Xanomeline and trospium chloride (formerly known as KarXT), a novel M1/M4 muscarinic receptor agonist, demonstrated efficacy across phase 2 and 3 trials as monotherapy for the treatment of inpatients with acute schizophrenia on the Positive and Negative Syndrome Scale total score primary endpoint. In the phase 2 trial, xanomeline/trospium improved performance on a cognitive outcome measure in the subgroup of participants with clinically significant baseline cognitive impairment. The authors sought to confirm this finding using data from two phase 3 trials. METHODS: Data were pooled from two 5-week inpatient trials of xanomeline/trospium monotherapy in patients with acute schizophrenia. The statistical analysis plan prespecified comparisons of cognitive composite score changes between xanomeline/trospium and placebo in the full sample and the cognitively impaired (≤1 SD below norms at baseline) subgroup. RESULTS: There was no significant xanomeline/trospium effect in the full sample (N=357); however, in the impaired subgroup, xanomeline/trospium (N=71) had a significantly greater benefit for cognition compared with placebo (N=66; least squares mean difference=0.31, SE=0.10; d=0.54). The xanomeline/trospium effect size increased significantly with a more stringent baseline impairment threshold (≤-1.5 SD; d=0.80). Improvements in cognition were minimally correlated with concurrent changes in total, positive, and negative symptoms in both treatment groups. CONCLUSIONS: Participants with acute schizophrenia with prespecified impairments demonstrated significant cognitive improvement with xanomeline/trospium compared with placebo. This result directly confirms earlier findings. This benefit is not attributable to changes in symptoms, despite substantial evidence of efficacy for psychosis. Evaluation of xanomeline/trospium's potential for cognitive enhancement in a well-controlled trial of stable patients with cognitive impairment is warranted.
引用
- Horan WP, Sauder C, Harvey PD, et al. The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials. Am J Psychiatry. 2024. PMID: 39659157. doi:10.1176/appi.ajp.20240076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。